一次情報の記録
Verricaは、追加の患者が必要ないという中間解析の結果を受け、共通いぼに対するYCANTHの2つのグローバル第3相主要試験(COVE-2)の最初の試験の登録を完了しました。2つの試験からのトップラインデータは2027年第1四半期と2027年半ばに予定されています。これは2026年第3四半期決算リリースにおける2026年8月27日の発表の要約です。
EX-99.1 2 d144356dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results – Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million – – Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively – – Company achieved pre-defined revenue, growth and operational milestones under credit facility to unlock full access to $27.5 million of non-dilutive growth capital and further extend cash runway through data readout for both common warts trials – – Company is now exploring the development of its onc